Canada Gazette, Part I, Volume 150, Number 52: GOVERNMENT NOTICES
December 24, 2016
DEPARTMENT OF CITIZENSHIP AND IMMIGRATION
IMMIGRATION AND REFUGEE PROTECTION ACT
Ministerial Instructions with respect to the processing of applications for permanent residence made by a foreign national as a sponsored spouse, common-law partner, conjugal partner or dependent child and the processing of sponsorship applications made in relation to those applications
These Instructions are published in the Canada Gazette in accordance with subsection 87.3(6) of the Immigration and Refugee Protection Act. These Instructions are given by the Minister of Citizenship and Immigration as, in the opinion of the Minister, these Instructions will best support the attainment of the immigration goals established by the Government of Canada by supporting the Government's commitment to reduce processing times for applications made by foreign nationals as members of the Family Class and the Spouse or Common-law Partner in Canada Class.
Scope
These Instructions are given pursuant to section 87.3 and subsections 92(1.1) and (2) of the Immigration and Refugee Protection Act (IRPA).
These Instructions apply to the applications for a permanent resident visa of the sponsor's spouse, common-law partner, conjugal partner or dependent child made under the Family Class and to applications to remain in Canada as a permanent resident of the sponsor's spouse or common-law partner made under the Spouse or Common-Law Partner in Canada Class referred to in paragraphs 117(1)(a) and (b) and section 124 of the Immigration and Refugee Protection Regulations (IRPR), respectively — as well as any sponsorship applications made in relation to those applications — that are received by the Department of Citizenship and Immigration (the Department) as of December 15, 2016.
Condition
In order to be processed, any application referred to in these Instructions that has not been returned under section 12 of the IRPR for not meeting the requirements of sections 10 and 11 of the IRPR — for example by not using all the applicable forms provided by the Department in the application package published on the website of the Department at the time the application is received by the Department or by not including all information, documents and evidence referred to in paragraph 10(1)(c) of the IRPR — must meet the condition of being accompanied by the following documents:
- (a) as amended from time to time, as the case may be,
- (i) the document entitled “Document Checklist — Spouse” [IMM 5533],
- (ii) the document entitled “Document Checklist — Common-Law Partner” [IMM 5589],
- (iii) the document entitled “Document Checklist — Conjugal Partner” [IMM 5629], or
- (iv) the document entitled “Document Checklist — Dependent Child” [IMM 5534]; and
- (b) the documents required in Part B of the applicable Document Checklist referred to in paragraph (a).
Disposition of applications
Any application referred to in these Instructions that does not meet the condition established in these Instructions will be returned, except the application made in accordance with the previous application package published on the website of the Department that is received by the Department during the period commencing on the day on which these Instructions take effect and ending on January 31, 2017.
Coming into effect
These Instructions take effect on December 15, 2016.
Ottawa, December 12, 2016
John McCallum
Minister of Citizenship and Immigration
[52-1-o]
DEPARTMENT OF THE ENVIRONMENT
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Ministerial Condition No. 18685
Ministerial condition
(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)
Whereas the Minister of the Environment and the Minister of Health have assessed information pertaining to the substance 1-propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-C8-18 acyl derivs., inner salts, Chemical Abstracts Service No. 97862-59-4;
And whereas the ministers suspect that the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999,
The Minister of the Environment, pursuant to paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999, hereby permits the manufacture or import of the substance in accordance with the conditions of the following annex.
George Enei
Assistant Deputy Minister
Science and Technology Branch
On behalf of the Minister of the Environment
ANNEX
Conditions
(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)
1. The following definitions apply in these ministerial conditions:
“engineered hazardous waste landfill facility” means a facility that is part of an overall integrated hazardous waste management system where wastes that do not require additional treatment or processing are sent and where hazardous materials are confined or controlled for the duration of their effective contaminating lifespan;
“notifier” means the person who has, on July 19, 2016, provided to the Minister of the Environment the prescribed information concerning the substance, in accordance with subsection 81(1) of the Canadian Environmental Protection Act, 1999;
“substance” means 1-propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-C8-18 acyl derivs., inner salts, Chemical Abstracts Service No. 97862-59-4; and
“waste” means the effluents that result from rinsing equipment or vessels used for the substance, disposable vessels used for the substance, any spillage that contains the substance, the process effluents that contain the substance, and any residual quantity of the substance in any equipment or vessel.
2. The notifier may import or manufacture the substance in accordance with the present ministerial conditions.
Restriction
3. The notifier shall not import or manufacture the substance, unless
- (a) the concentration of 1,3-propanediamine, N,N-dimethyl-, Chemical Abstracts Service No. 109-55-7 in the substance is less than 0.01% by weight; and
- (b) the concentration of fatty acid amidopropyl dimethylamine (amidoamine) impurities in the substance is equal to or less than 1.5% by weight.
Handling of the substance
4. The notifier or the person to whom the substance has been transferred shall not release the substance or waste to the environment.
Disposal of the substance
5. The notifier or the person to whom the substance has been transferred must collect any waste in their physical possession or under their control and destroy or dispose of it in the following manner:
- (a) incineration in accordance with the laws of the jurisdiction where the incineration facility is located; or
- (b) disposal in an engineered hazardous waste landfill facility, in accordance with the laws of the jurisdiction where the facility is located, if it cannot be incinerated in accordance with paragraph (a).
Environmental release
6. Where any release of the substance or waste to the environment occurs, the person who has the physical possession or control of the substance or waste shall immediately take all measures necessary to prevent any further release, and to limit the dispersion of any release. Furthermore, the person shall, as soon as possible in the circumstances, inform the Minister of the Environment by contacting an enforcement officer designated under the Canadian Environmental Protection Act, 1999.
Record-keeping requirements
7. (1) The notifier shall maintain electronic or paper records, with any documentation supporting the validity of the information contained in these records, indicating
- (a) the use of the substance;
- (b) that 1,3-propanediamine, N,N-dimethyl-, Chemical Abstracts Service No. 109-55-7 is present or not in the substance imported or manufactured, and if present, its concentration by weight;
- (c) that fatty acid amidopropyl dimethylamine (amidoamine) impurities are present or not in the substance imported or manufactured, and if present, their concentration by weight;
- (d) the quantity of the substance that the notifier manufactures, imports, purchases, sells and uses;
- (e) the name and address of each person to whom the notifier transfers the physical possession or control of the substance; and
- (f) the name and address of each person in Canada who disposed of the substance or of the waste for the notifier, the method used to do so and the quantities of the substance or waste shipped to that person.
(2) The notifier shall maintain electronic or paper records mentioned in subsection (1) at their principal place of business in Canada, or at the principal place of business in Canada of their representative, for a period of at least five years after they are made.
Other requirements
8. The notifier shall inform any person to whom they transfer the physical possession or control of the substance or of the waste, in writing, of the terms of the present ministerial conditions. The notifier shall obtain, prior to the first transfer of the substance or waste, written confirmation from this person that they were informed of the terms of the present ministerial conditions. This written confirmation shall be maintained at the principal place of business in Canada of the notifier or of their representative in Canada for a period of at least five years from the day it was received.
Coming into force
9. These ministerial conditions come into force on December 7, 2016.
[52-1-o]
DEPARTMENT OF HEALTH
CONTROLLED DRUGS AND SUBSTANCES ACT
Notice to interested parties — Proposed order amending Schedule III to the Controlled Drugs and Substances Act and proposed regulations amending the schedule to Part G of the Food and Drug Regulations to expand the scheduling entry for aminorex and its salts
This notice provides interested stakeholders with the opportunity to comment on Health Canada's intent to amend Schedule III to the Controlled Drugs and Substances Act (CDSA) in order to expand the scheduling entry for aminorex and its salts to include its derivatives, isomers and analogues, as well as salts of the derivatives, isomers and analogues. The listing of aminorex and its salts will be similarly expanded in Part 1 of the schedule to Part G of the Food and Drug Regulations (FDR). In the interest of clarity, 4-MAR and 4,4′-DMAR, both of which are analogues of aminorex, would also be listed in these schedules to the CDSA and to Part G of the FDR. The current entry of 4-MAR and its salts will be removed from the schedule to Part J to the FDR.
Aminorex and its salts are currently controlled under Schedule III to the CDSA and Part G of the FDR. The derivatives, isomers and analogues of aminorex (as well as salts of derivatives, isomers and analogues) currently have no approved therapeutic uses in Canada; however, Health Canada is proposing to also list them under Part G of the FDR, which would facilitate legitimate use in the future, should therapeutic uses emerge. This expansion of the listing of aminorex and its salts would capture 4,4′-DMAR, an analogue of aminorex, which was added to Schedule II to the Convention on Psychotropic Substances, 1971 at the 59th Commission on Narcotic Drugs in Vienna, Austria, in March 2016. This regulatory amendment will ensure Canada meets its international obligations.
Available data suggests that there is a potential for abuse and/or addiction to 4,4′-DMAR. The substance is reported to have numerous toxic effects, including risk of death, and has been linked to 46 deaths internationally.
The CDSA is the legislation through which the Government of Canada fulfills its international obligations under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. The CDSA and its regulations provide a legislative framework for the control of substances that can alter mental processes and that may cause harm to individuals or to society when diverted to an illicit market or use. The CDSA and its regulations have the dual purpose of protecting public health and maintaining public safety by permitting access to these substances for legitimate industrial, medical or scientific purposes, while mitigating the risks of trafficking and diversion to illicit markets and uses.
Part G of the FDR provides a licensing and permitting framework authorizing licensed dealers to conduct activities with substances specified on their licences. For example, only licensed dealers are authorized to engage in activities such as production, manufacture, assembly, importation, exportation, sale, provision, delivery or transportation of controlled substances.
The publication of this notice in the Canada Gazette, Part I, initiates a 30-day comment period. Anyone interested in this process or anyone who has comments about this notice should contact Legislative and Regulatory Affairs, Controlled Substances Directorate, Healthy Environments and Consumer Safety Branch, Health Canada, by mail at Address Locator: 0302A, 150 Tunney's Pasture Driveway, Ottawa, Ontario K1A 0K9, or by email at ocs_regulatorypolicy-bsc_politiquereglementaire@hc-sc.gc.ca.
December 24, 2016
Ana G. Renart
Director General
Controlled Substances Directorate
[52-1-o]
DEPARTMENT OF INDUSTRY
OFFICE OF THE REGISTRAR GENERAL
| Name and position | Order in Council |
|---|---|
National Energy Board
|
|
Nunavut Court of Justice
|
|
Shaw, The Hon. Douglas C.
|
|
Warkentin, The Hon./L'hon. Bonnie R.
|
|
Whalen, The Hon.
|
|
December 16, 2016
Diane Bélanger
Official Documents Registrar
[52-1-o]
DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS
CRIMINAL CODE
Two-year review of list of entities established pursuant to section 83.05 of the Criminal Code
Whereas subsection 83.05(9) (see footnote a) of the Criminal Code (see footnote b) requires the Minister of Public Safety and Emergency Preparedness to review the list established under subsection 83.05(1) (see footnote c) of that Act two years after its establishment, and every two years after that, to determine whether there are still reasonable grounds for an entity to remain a listed entity as set out in subsection 83.05(1) (see footnote d) of that Act;
Whereas, on July 23, 2016, 14 years had elapsed since the establishment of the list by the Regulations Establishing a List of Entities (see footnote e) pursuant to subsection 83.05(1) (see footnote f) of the Criminal Code (see footnote g);
And whereas, pursuant to subsection 83.05(9) (see footnote h) of the Criminal Code (see footnote i), the Minister of Public Safety and Emergency Preparedness has carried out the review of the list as it existed on July 23, 2016;
Therefore, notice is given, pursuant to subsection 83.05(10) (see footnote j) of the Criminal Code (see footnote k), that the Minister of Public Safety and Emergency Preparedness completed the review on November 20, 2016.
Ralph Goodale
Minister of Public Safety and Emergency Preparedness
[52-1-o]
GLOBAL AFFAIRS CANADA
Consultations on the fifth review of the Record of Discussion on Trade in Pharmaceutical Products
The Government of Canada is seeking the views of Canadians on a proposed fifth review of the 1994 Record of Discussion on Trade in Pharmaceutical Products (the “arrangement”) concluded among the following World Trade Organization (WTO) members: Canada, the European Union (EU), Japan, Macao (China), Norway, Switzerland, and the United States.
Background
Pursuant to the 1994 arrangement, participating WTO members have eliminated their duties, on a Most Favoured Nation basis, for specified pharmaceutical ingredients and intermediates.
The Record of Discussion was notified by the participating WTO members on March 25, 1994, and covered over 6 000 pharmaceutical-related products. To expand the coverage of tariff elimination to new pharmaceutical-related products developed after 1994, the Record of Discussion provides for the periodic review of the product coverage. Four earlier reviews occurred in 1996, 1998, 2007 and 2010. As a result of the reviews, the arrangement currently covers nearly 9 000 pharmaceutical-related products.
With respect to a fifth review of the arrangement, it has been suggested that the coverage of the arrangement be expanded to include additional compounds published by the World Health Organization (WHO) as Proposed International Nonproprietary Names (lists are available at www.who.int/medicines/publications/druginformation/innlists/en/).
Submissions by interested parties
The Government of Canada is seeking to identify the interests of Canadians in terms of product coverage as well as any concerns with the proposed elimination of Canadian tariffs for these products. To help inform this process, the Government is embarking on a public consultation process to give all interested stakeholders an opportunity to provide input. Interested parties wishing to contribute to this process are invited to provide responses to the following three questions:
- Do you support the proposed fifth review of the product scope of the Record of Discussion on the Trade in Pharmaceutical Products? Please provide a rationale for your response.
- Do you face tariff barriers in any participant countries with respect to exports of pharmaceutical ingredients or intermediates? If so, are they related to specific pharmaceutical ingredients or intermediates? Please provide the Harmonized System (HS) subheading codes.
- Do you have any views on the elimination of Canadian import tariffs on the pharmaceutical ingredients and intermediates listed by the WHO? If so, please provide a description of the ingredients or intermediates and their HS subheading codes.
The deadline for receiving input and comments is March 10, 2017. Please be advised that any information received as a result of this consultation will be considered public information, unless explicitly designated as private. Submissions should include the contributor's name and address and, if applicable, his or her organization, institution or business.
Additional information
For more information on the Record of Discussions of the Trade in Pharmaceutical Products, please consult: https://www.wto.org/gatt_docs/English/SULPDF/91770009.pdf.
Contact points
Questions and contributions may be sent by mail or email to WTO Pharmaceutical Initiative, Tariffs and Goods Market Access Division (TPG), Global Affairs Canada, 111 Sussex Drive, Ottawa, Ontario K1A 0G2; email: tpg@international.gc.ca.
Questions or comments regarding the Canadian tariffs should be sent by mail or email to WTO Pharmaceutical Initiative, International Trade Policy Division, Department of Finance, 90 Elgin Street, 14th Floor, Ottawa, Ontario K1A 0G5; email: fin.tariff-tarif.fin@canada.ca.
[52-1-o]
OFFICE OF THE SUPERINTENDENT OF FINANCIAL INSTITUTIONS
INSURANCE COMPANIES ACT
Brookfield Annuity Company — Order to commence and carry on business
Notice is hereby given of the issuance, pursuant to subsection 53(1) of the Insurance Companies Act, of an order to commence and carry on business authorizing Brookfield Annuity Company, and, in French, La Compagnie de Rentes Brookfield, to commence and carry on business, effective October 3, 2016.
December 8, 2016
Jeremy Rudin
Superintendent of Financial Institutions
[52-1-o]
PRIVY COUNCIL OFFICE
Appointment opportunities
We know that our country is stronger — and our government more effective — when decision-makers reflect Canada's diversity. Moving forward, the Government of Canada will use an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous Canadians and minority groups are properly represented in positions of leadership. We will continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.
The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.
Current opportunities
The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments website (http://www.appointmentsnominations.gc.ca/slctnPrcs.asp?menu=1&lang=eng).
| Position | Organization | Closing date |
|---|---|---|
| Chairperson | Canadian Centre on Substance Abuse | January 16, 2017 |
| Director | Canadian Centre on Substance Abuse | January 16, 2017 |
| Full-time and part-time members | Canadian Human Rights Tribunal | January 9, 2017 |
| Members | Canadian Institutes of Health Research | January 16, 2017 |
| Chairperson | Canadian Museum for Human Rights | January 23, 2017 |
| Trustees | Canadian Museum for Human Rights | January 9, 2017 |
| Chairperson | Canadian Museum of History | January 23, 2017 |
| Trustees | Canadian Museum of History | January 9, 2017 |
| Vice-Chairperson | Canadian Museum of History | January 23, 2017 |
| Chairperson | Canadian Museum of Immigration at Pier 21 | January 23, 2017 |
| Trustees | Canadian Museum of Immigration at Pier 21 | January 9, 2017 |
| Chairperson | Canadian Museum of Nature | January 23, 2017 |
| Trustees | Canadian Museum of Nature | January 9, 2017 |
| Permanent Members | Canadian Nuclear Safety Commission | January 16, 2017 |
| Chief Science Advisor | Innovation, Science and Economic Development Canada | January 27, 2017 |
| Chairperson | National Gallery of Canada | January 23, 2017 |
| Trustees | National Gallery of Canada | January 9, 2017 |
| Vice-Chairperson | National Gallery of Canada | January 23, 2017 |
| Members | National Film Board | January 15, 2017 |
| Trustees | National Museum of Science and Technology | January 9, 2017 |
| Commissioner of Lobbying | Office of the Commissioner of Lobbying | January 9, 2017 |
| Commissioner of Official Languages for Canada | Office of the Commissioner of Official Languages | January 9, 2017 |
| Conflict of Interest and Ethics Commissioner | Office of the Conflict of Interest and Ethics Commissioner | January 9, 2017 |
| Chairperson | Payment in Lieu of Taxes Dispute Advisory Panel | January 15, 2017 |
| Members | Payment in Lieu of Taxes Dispute Advisory Panel | January 15, 2017 |
| Chief Public Health Officer | Public Health Agency of Canada | February 12, 2017 |
| Member | Telefilm Canada | January 15, 2017 |
Upcoming opportunities
New opportunities that will be posted in the coming weeks.
| Position | Organization |
|---|---|
| President (Chief Executive Officer) | Atomic Energy of Canada Limited |
| Commissioner for Workers | Canada Employment Insurance Commission |
| Chairperson | Canada Foundation for Innovation |
| President | Canadian Centre for Occupational Health and Safety |
| Chairperson | Canadian International Trade Tribunal |
| Directors | Canadian Race Relations Foundation |
| Citizenship Judges | Citizenship Commission |
| Directors | First Nations Financial Management Board |
| Clerk of the House of Commons | House of Commons |
| Sergeant-at-Arms | House of Commons |
| Directors | Jacques Cartier and Champlain Bridges Incorporated |
| Members | National Arts Centre Corporation |
| Chairperson | National Battlefields Commission |
| Commissioner | National Battlefields Commission |
| Full-time Member | National Energy Board |
| Director of Public Prosecutions | Office of the Director of Public Prosecutions |
| Procurement Ombudsman | Office of the Procurement Ombudsman |
| Executive Vice-Chairperson and Member | Parole Board of Canada |
| Chairperson | Patented Medicine Prices Review Board |
| Member | Patented Medicine Prices Review Board |
| Directors | Royal Canadian Mint |
| Chairperson and Member | Standards Council of Canada |
Ongoing opportunities
Opportunities posted on an ongoing basis.
| Position | Organization |
|---|---|
| Full-time and Part-time Members | Immigration and Refugee Board |
| Members — All regional divisions (full-time positions and part-time positions) | Parole Board of Canada |
| Full-time and Part-time Members (Appeal Division) | Social Security Tribunal |
| Full-time and Part-time Members (General Division — Employment Insurance Section) | Social Security Tribunal |
| Full-time and Part-time Members (General Division — Income Security Section) | Social Security Tribunal |
[52-1-o]
BANK OF CANADA
Statement of financial position as at November 30, 2016
| ASSETS | Amount | Total |
|---|---|---|
| Cash and foreign deposits | 14.6 | |
| Loans and receivables | ||
| Securities purchased under resale agreements | 7,002.4 | |
| Advances to members of Payments Canada (see footnote *) | — | |
| Advances to governments | — | |
| Other receivables | 6.3 | |
| 7,008.7 | ||
| Investments | ||
| Treasury bills of Canada | 16,646.1 | |
| Government of Canada bonds | 79,074.1 | |
| Other investments | 403.7 | |
| 96,123.9 | ||
| Property and equipment | 552.3 | |
| Intangible assets | 34.4 | |
| Other assets | 35.6 | |
| Total assets | 103,769.5 | |
| LIABILITIES AND EQUITY | Amount | Total |
|---|---|---|
| Bank notes in circulation | 77,726.9 | |
| Deposits | ||
| Government of Canada | 22,548.9 | |
| Members of Payments Canada | 488.7 | |
| Other deposits | 1,847.3 | |
| 24,884.9 | ||
| Liabilities in foreign currencies | ||
| Government of Canada | — | |
| Other | — | |
| — | ||
| Other liabilities | ||
| Securities sold under repurchase agreements | — | |
| Other liabilities | 661.6 | |
| 661.6 | ||
| 103,273.4 | ||
| Equity | ||
| Share capital | 5.0 | |
| Statutory and special reserves | 125.0 | |
| Available-for-sale reserve | 366.1 | |
| Actuarial gains reserve | — | |
| Retained earnings | — | |
| 496.1 | ||
| Total Liabilities and Equity | 103,769.5 | |
I declare that the foregoing return is correct according to the books of the Bank.
Ottawa, December 15, 2016
Carmen Vierula
Chief Financial Officer and Chief Accountant
I declare that the foregoing return is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.
Ottawa, December 15, 2016
Stephen S. Poloz
Governor
[52-1-o]